IPCA LABORATORIES LTD.

Ipca Laboratories Ltd has announced the closure of its trading window for dealing in the company's securities by insiders. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be closed effective October 1st, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the second quarter and half-year ended September 30th, 2026. The specific date for the board meeting to consider these financial results will be communicated separately.

Ipca Laboratories Ltd announced its Standalone and Consolidated Unaudited Financial Results for the first quarter ended June 30, 2026. The Board of Directors approved and took on record these results, along with the limited review reports from the company's auditors. The financial statements were prepared in accordance with Indian Accounting Standards (IND-AS) and comply with SEBI regulations. The company also noted an impact from new Labour Codes, affecting gratuity and leave liabilities.

Ipca's Q1 FY27 print is unambiguously strong on a year-on-year basis: consolidated PAT of ₹401.89 Cr rose 72% YoY (the company's own release cites 80% using a pre-minority-interest base of ₹422.81 Cr), on consolidated revenue of ₹2,788.10 Cr, up 21% YoY and 16.7% QoQ. Standalone PAT was ₹373.29 Cr, up 42% YoY, on revenue of ₹2,119.24 Cr, also up 21%. Neither period carries an exceptional item this quarter, making it a clean read against Q4 FY26, which had absorbed a ₹45.82 Cr (consolidated) labour-code exceptional charge. The margin story is the real driver: consolidated EBITDA margin (before forex and other income) expanded to 22.88% from 18.39% a year ago, and standalone margin to 26.27% from 23.82%. Consolidated total expenses grew only ~11.5% (₹2,241.28 Cr vs ₹2,011.00 Cr) against 21% revenue growth — clear operating leverage, not a forex artifact, since the EBITDA metric already excludes forex (which itself swung favorable: a ₹31.57 Cr consolidated gain versus an ₹8.16 Cr loss a year ago). Mix also helped: institutional export formulations jumped 107% YoY to ₹119.75 Cr, generics exports rose 27% to ₹340.02 Cr and API exports grew 33% to ₹332.35 Cr — export income overall (+34% standalone) comfortably outpaced domestic formulations (+13%). No independent analyst consensus for this print turned up in a web search, so the reading is against our own pre-result preview, which flagged expected revenue of ~₹1,850–1,900 Cr, an EBITDA margin watch of 21–23%, and organic growth of 10%+ as the bar — the actual print clears all three (standalone revenue ₹2,119 Cr, consolidated EBITDA margin 22.9%, revenue growth 21% YoY). Against management's own FY27 guidance from the June 4, 2026 concall — consolidated revenue growth of 12–13% and EBITDA margin improving to 22–22.3% from 20.7% — Q1 is already running ahead of pace on both counts, with margin printing at the top of the full-year target in the very first quarter. Domestic branded formulations grew 13%, roughly matching the guided ~12%. The Krebs Biochemicals amalgamation, board-approved June 26, 2026 with an April 1, 2026 appointed date, remains pending consents and is not yet reflected in these numbers. The ₹6/share dividend (record date August 7) and today's AGM are procedural, not P&L-relevant. With both growth and margin ahead of the full-year guide after just one quarter, the bar for the rest of FY27 rises. What it sets up: whether the 22.9% consolidated EBITDA margin holds once Krebs is consolidated and once Unichem's separately-guided 12–13% margin target (not broken out this quarter) shows up in the numbers.

Ipca Laboratories Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda for this meeting is to consider and approve the standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026. The company also confirmed that the trading window for insiders will remain closed from July 1, 2026, until 48 hours after the declaration of these financial results, extending to August 15, 2026.

Ipca Laboratories Ltd has announced the details for its 76th Annual General Meeting (AGM) scheduled for August 13, 2026, to be held via Video Conferencing. The company is providing a web link to its Annual Report for shareholders who have not registered their email addresses. This communication also serves as a reminder for shareholders holding physical securities to update their KYC details, including PAN, address, bank account, and nomination, as mandated by SEBI regulations, to ensure continued eligibility for payments like dividends. Shareholders are encouraged to update their email addresses for easier access to information and to support green initiatives.

Ipca Laboratories Ltd has announced Friday, August 7, 2026, as the record date for determining shareholders' entitlement to a dividend, which is proposed at ₹6 per share (600%). This dividend, if sanctioned at the Annual General Meeting scheduled for August 13, 2026, will be paid on or before September 10, 2026. The record date ensures that only shareholders registered by August 7, 2026, will receive the dividend payment. The company has also confirmed that there is no book closure period for this event.

Ipca Laboratories Limited announced its 76th Annual General Meeting (AGM) will be held on Thursday, August 13, 2026, at 3:30 p.m. via Video Conferencing/Other Audio Visual Means (VC/OAVM). The company has recommended a dividend of ₹6 per share (600%) for the financial year ended March 31, 2026. The record date for dividend entitlement is Friday, August 7, 2026, with the dividend payment expected on or before September 10, 2026. The Annual Report 2025-26 has been dispatched electronically, and members can access it on the company's website. E-voting facilities will be available from August 10 to August 12, 2026.

Ipca Laboratories Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's corporate identity, registered and corporate addresses, and contact information for queries. It covers business activities, products, operations across national and international locations, employee details including gender and differently-abled representation, and turnover rates. The BRSR also outlines the company's subsidiaries and their participation in business responsibility initiatives. The reporting boundary is standalone, and assurance has been obtained for BRSR Core (Reasonable) and the remaining BRSR (Limited).

Ipca Laboratories Ltd has filed its Annual Report for the financial year ended March 31, 2026. The report highlights a significant increase in total income, reaching ₹7431.39 Crores, up from ₹6749.21 Crores in the previous fiscal year. Both domestic and export income have shown growth. The company also reported a substantial rise in Net Profit after Tax to ₹1132.52 Crores from ₹650.76 Crores in FY25. Dividend payout has increased to 600% for FY26. The report details the company's financial performance, corporate governance, and sustainability initiatives over the past decade.

Ipca Laboratories Ltd. announced its Board of Directors has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The merger is subject to regulatory approvals. The Appointed Date for the scheme is April 1, 2026. Ipca Laboratories had a total income of ₹7431 Crores for FY26, while Krebs Biochemicals had ₹26 Crores. The transaction is considered a related party transaction but will be conducted on an arm's length basis. Both companies operate in pharmaceutical manufacturing and marketing. The rationale includes operational synergies, cost optimization, business consolidation, and securing supply chains for key APIs and intermediates. Krebs Biochemicals possesses manufacturing capabilities for fermentation-based APIs that Ipca lacks. No cash consideration will be paid; instead, Ipca will issue 7 equity shares for every 200 shares of Krebs.